• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

经内镜治疗的上尿路移行细胞癌的长期随访

Long-term follow-up of endoscopically treated upper urinary tract transitional cell carcinoma.

作者信息

Elliott D S, Blute M L, Patterson D E, Bergstralh E J, Segura J W

机构信息

Department of Urology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA.

出版信息

Urology. 1996 Jun;47(6):819-25. doi: 10.1016/S0090-4295(96)00043-X.

DOI:10.1016/S0090-4295(96)00043-X
PMID:8677570
Abstract

OBJECTIVES

This report focuses on the long-term follow-up of patients with endoscopically treated upper tract transitional cell carcinoma (TCC) to determine the effectiveness of endoscopic therapy.

METHODS

From May 1983 to April 1994, 44 patients with TCC of the upper urinary tract underwent conservative endourologic treatment with either electrocautery fulguration or neodymium:yttrium-aluminum-garnet laser at our institution. The mean follow-up period was 5 years (range, 3 months to 11 years).

RESULTS

Renal pelvic tumor sizes ranged from 0.4 to 4.0 cm (mean, 1.5) and ureteral tumors from 0.2 to 1.0 cm (mean, 0.5). The majority of tumors were of pathologic grade 3 or less, and all were Stage T2 or less. Seventeen of 44 patients (38.6%) had local tumor recurrence (mean time to recurrence, 12.8 months; range 1.5 to 64). Mean recurrence time was 7.3 months for renal pelvic tumors and 17.8 months for ureteral tumors. Nineteen of 44 patients (43.2%) developed bladder tumors. The overall 5-year disease-free rate was 57%. No recurrent tumor was shown to have increased in grade, and one recurrent tumor was proved to have progressed in stage. Six patients (14%) ultimately required a nephroureterectomy for recurrence. There were no major complications as a result of endoscopic therapy. Six patients (14%) died of the effects of metastatic TCC, 5 of whom had known muscle invasive bladder TCC.

CONCLUSIONS

Endourologic techniques and the conservative treatment of upper urinary tract TCC is an evolving field and can be safely and effectively used as a first-line treatment for upper tract TCC in selected patients.

摘要

目的

本报告聚焦于经内镜治疗的上尿路移行细胞癌(TCC)患者的长期随访,以确定内镜治疗的有效性。

方法

1983年5月至1994年4月,44例上尿路TCC患者在我院接受了保守性腔内泌尿外科治疗,采用电灼凝固术或钕:钇铝石榴石激光治疗。平均随访期为5年(范围3个月至11年)。

结果

肾盂肿瘤大小为0.4至4.0厘米(平均1.5厘米),输尿管肿瘤为0.2至1.0厘米(平均0.5厘米)。大多数肿瘤病理分级为3级或更低,且均为T2期或更低。44例患者中有17例(38.6%)出现局部肿瘤复发(平均复发时间12.8个月;范围1.5至64个月)。肾盂肿瘤平均复发时间为7.3个月,输尿管肿瘤为17.8个月。44例患者中有19例(43.2%)发生膀胱肿瘤。总体5年无病生存率为57%。未发现复发性肿瘤分级增加,且有1例复发性肿瘤被证实分期进展。6例患者(14%)最终因复发需要行肾输尿管切除术。内镜治疗未导致重大并发症。6例患者(14%)死于转移性TCC的影响,其中5例已知有肌肉浸润性膀胱TCC。

结论

腔内泌尿外科技术及上尿路TCC的保守治疗是一个不断发展的领域,在部分患者中可安全有效地用作上尿路TCC的一线治疗方法。

相似文献

1
Long-term follow-up of endoscopically treated upper urinary tract transitional cell carcinoma.经内镜治疗的上尿路移行细胞癌的长期随访
Urology. 1996 Jun;47(6):819-25. doi: 10.1016/S0090-4295(96)00043-X.
2
Is nephroureterectomy necessary in all cases of upper tract transitional cell carcinoma? Long-term results of conservative endourologic management of upper tract transitional cell carcinoma in individuals with a normal contralateral kidney.对于所有上尿路移行细胞癌病例,肾输尿管切除术是否必要?对侧肾脏正常的个体中上尿路移行细胞癌保守性腔内治疗的长期结果。
Urology. 2001 Aug;58(2):174-8. doi: 10.1016/s0090-4295(01)01109-8.
3
Endoscopic management of upper tract transitional cell carcinoma in patients with normal contralateral kidneys.对侧肾脏正常的患者上尿路移行细胞癌的内镜治疗
Urology. 2008 Apr;71(4):713-7. doi: 10.1016/j.urology.2007.11.018. Epub 2008 Feb 11.
4
Pathologic features of bladder tumors after nephroureterectomy or segmental ureterectomy for upper urinary tract transitional cell carcinoma.上尿路移行细胞癌行肾输尿管切除术或输尿管节段切除术后膀胱肿瘤的病理特征。
Urology. 2007 Feb;69(2):251-4. doi: 10.1016/j.urology.2006.09.065.
5
Superficial transitional cell carcinoma of the ureteral orifice: higher risk of developing subsequent upper urinary tract tumors.输尿管口浅表移行细胞癌:发生后续上尿路肿瘤的风险更高。
Int J Urol. 2006 Jun;13(6):682-5. doi: 10.1111/j.1442-2042.2006.01385.x.
6
Postoperative radiation therapy in 26 patients with invasive transitional cell carcinoma of the upper urinary tract: no impact on survival?26例上尿路浸润性移行细胞癌患者的术后放射治疗:对生存无影响?
J Urol. 1996 Jan;155(1):115-7.
7
Oncologic control after open or laparoscopic nephroureterectomy for upper urinary tract transitional cell carcinoma: a single center experience.开放性或腹腔镜下肾输尿管切除术治疗上尿路移行细胞癌后的肿瘤控制:单中心经验
Urology. 2007 Apr;69(4):656-61. doi: 10.1016/j.urology.2007.01.007.
8
The outcome of patients on dialysis with upper urinary tract transitional cell carcinoma.接受透析治疗的上尿路移行细胞癌患者的治疗结果。
J Urol. 2006 Aug;176(2):477-81. doi: 10.1016/j.juro.2006.03.099.
9
Risk factors for intravesical recurrence after surgical management of transitional cell carcinoma of the upper urinary tract.上尿路移行细胞癌手术治疗后膀胱内复发的危险因素。
Urology. 2008 Jan;71(1):123-7. doi: 10.1016/j.urology.2007.08.054.
10
Elective endoscopic management of transitional cell carcinoma first diagnosed in the upper urinary tract.首次诊断于上尿路的移行细胞癌的择期内镜治疗。
BJU Int. 2008 Nov;102(9):1107-10. doi: 10.1111/j.1464-410X.2008.07766.x. Epub 2008 Jun 3.

引用本文的文献

1
Current Evidence on Utility, Outcomes, and Limitations of Endoscopic Laser Ablation for Localized Upper Urinary Tract Urothelial Carcinoma: Results from a Scoping Review.内镜激光消融治疗局限性上尿路尿路上皮癌的效用、结果及局限性的当前证据:一项范围综述的结果
Eur Urol Open Sci. 2023 Dec 19;59:7-17. doi: 10.1016/j.euros.2023.11.005. eCollection 2024 Jan.
2
A Review of How Lasers Are Used in UTUC Surgery: Can the Choice of Laser Affect Outcomes?激光在UTUC手术中的应用综述:激光的选择会影响手术结果吗?
Cancers (Basel). 2023 Mar 21;15(6):1874. doi: 10.3390/cancers15061874.
3
Future strategies to enhance kidney preservation in upper urinary tract urothelial carcinoma.
提高上尿路尿路上皮癌肾脏保存的未来策略。
Transl Androl Urol. 2020 Aug;9(4):1831-1840. doi: 10.21037/tau.2019.11.09.
4
Outcomes of endoscopic management of upper tract urothelial carcinoma.上尿路尿路上皮癌的内镜治疗结果
Transl Androl Urol. 2020 Aug;9(4):1821-1830. doi: 10.21037/tau.2019.12.26.
5
Importance of long-term follow-up after endoscopic management for upper tract urothelial carcinoma and factors leading to surgical management.重视上尿路尿路上皮癌内镜治疗后的长期随访及导致外科治疗的因素。
Int Urol Nephrol. 2020 Aug;52(8):1465-1469. doi: 10.1007/s11255-020-02439-5. Epub 2020 Mar 11.
6
Early repeated ureteroscopy within 6-8 weeks after a primary endoscopic treatment in patients with upper tract urothelial cell carcinoma: preliminary findings.上尿路尿路上皮癌患者初次内镜治疗后6 - 8周内早期重复输尿管镜检查:初步结果
World J Urol. 2016 Sep;34(9):1201-6. doi: 10.1007/s00345-015-1753-7. Epub 2015 Dec 23.
7
Nephron-sparing Management of Upper Tract Urothelial Carcinoma.上尿路尿路上皮癌的保留肾单位治疗
Rev Urol. 2014;16(1):21-8.
8
Intracavitary immunotherapy and chemotherapy for upper urinary tract cancer: current evidence.腔内免疫疗法与化疗在上尿路癌中的应用:当前证据
Rev Urol. 2013;15(4):145-53.
9
Canadian guidelines for postoperative surveillance of upper urinary tract urothelial carcinoma.加拿大上尿路尿路上皮癌术后监测指南。
Can Urol Assoc J. 2013 Sep-Oct;7(9-10):306-11. doi: 10.5489/cuaj.1578.
10
Mitomycin C instillation following ureterorenoscopic laser ablation of upper urinary tract carcinoma.输尿管软镜激光消融上尿路癌后丝裂霉素C灌注
Urol Ann. 2013 Jul;5(3):184-9. doi: 10.4103/0974-7796.115746.